When and how a combination of antiepileptic drugs (AEDs) should be used in patients unresponsive to monotherapy is not known. We followed up prospectively 248 patients in whom treatment with the first AED was unsuccessful. When treatment failed due to intolerable adverse events, a second (substituted) drug was prescribed. When failure was due to lack of efficacy, either AED substitution or combination (add-on) was undertaken. Patients were considered to be seizure-free if they had no seizures for at least 1 year. Among patients with inadequate seizure control on the first well tolerated AED, those who received substituted monotherapy (n = 35) and those who received add-on treatment (n = 42) had similar seizure-free rates (substitution vs. add-on: 17% vs. 26%) and incidence of intolerable side effects (substitution vs. add-on: 26% vs. 12%). Based on the drugs' perceived primary mode of action, more patients became seizure-free when the combination involved a sodium channel blocker and a drug with multiple mechanisms of action (36%) compared to other combinations (7%, P = 0.05). None of the 11 patients who received add-on treatment after a second drug had also failed became seizure-free, compared to 26% in those who received add-on as soon as the first tolerated AED proved to be ineffective (n = 42, P = 0.05). These preliminary observations have generated verifiable hypotheses regarding the early management of epilepsy. A randomized study comparing substitution and combination after the failure of the first AED is underway.
INTRODUCTION
Up to one third of patients continue to have seizures despite antiepileptic drug (AED) treatment 1, 2 . Uncontrolled epilepsy is associated with excess mortality 3 , cognitive and behavioural dysfunction 4 , and social and educational disadvantage 5 for which society pays a high price 6 . Long-term outcome studies 2 and randomized trials [7] [8] [9] [10] suggest that fewer than 50% of patients will become seizure-free on the first AED. An alternative drug (substitution) is unavoidable when the patient develops intolerable adverse events, but when seizures persist despite a sufficient dose of the first AED, it is unclear whether or not substitution should be tried before combining drugs 11 .
This controversy arises largely because the 'natural history' of newly diagnosed epilepsy in response to treatment is not well understood. Since the advantages of single-over multiple-drug treatment, particularly in terms of side effect profile, were demonstrated by a series of studies in the late 1970s and early 1980s [12] [13] [14] [15] [16] , monotherapy has rightly become the established principle for managing new onset epilepsy. However, the explosion of new AEDs in the past decade with their mechanistic diversity 17, 18 and generally better tolerability 19 has raised the possibility of effective and safe combinations for patients unresponsive to monotherapy 20 . We examined the effectiveness of substitution and add-on therapy after treatment with the first AED failed in a prospective cohort of newly diagnosed patients followed up since January 1984 at a single centre. 19, 21 . After commencement of medication, patients were reviewed at the epilepsy clinic every 4-6 weeks for the first 6 months and at least every 4 months thereafter. A dedicated telephone line was set up for the patients or their primary care physicians to contact the Epilepsy Unit should problems arise between scheduled clinic appointments.
MATERIALS AND METHODS

This
Compliance was monitored as necessary at the clinic with the aid of on-site measurement of serum AED concentration 22 . Dosages were titrated according to recommended schedules 23, 24 and adjusted during follow-up as clinical circumstances dictated paying particular attention to efficacy and tolerability. Each patient's clinical information and response to treatment were recorded in a prospective database 25 .
Response to medication was classified as seizurefree (absence of any type of seizures or auras for at least 1 year); failure of treatment due to inadequate seizure control despite ability to tolerate the medication (lack of efficacy) or due to adverse events (including intolerable side effects and idiosyncratic reactions); or withdrawal of treatment for reasons unrelated to efficacy or tolerability such as concern about potential adverse events, planning a pregnancy, and a change of mind. A change of drug regimen was defined as either substitution by alternative monotherapy or addition of another drug. Patients who developed idiosyncratic reactions or intolerable side effects were treated with an alternative drug (substitution). When seizure control was inadequate, either substitution or combination (add-on) was prescribed.
Patients in whom the first AED was replaced by an alternative were analysed according to the reason for substitution. In order to address the clinical question of appropriate treatment strategy for patients who experienced persistent seizures despite being able to tolerable the medication, we compared the response to substitution and add-on therapy in those with inadequate seizure control on the first well tolerated AED. AEDs were classified according to their putative primary mode of action 17, 18 . Drugs that primarily act on voltage-gated sodium channels include carbamazepine, phenytoin and lamotrigine. Vigabatrin and tiagabine enhance the inhibitory function of γ -aminobutyric acid (GABA). Sodium valproate, gabapentin and topiramate are classified as having multiple mechanisms of action. The chi-squared test and Fisher's exact test were used for comparisons of categorical data. All statistical tests were two-tailed. Calculations were made using Minitab for Windows (Release 11.21) software.
RESULTS
Among 470 previously untreated newly diagnosed patients referred to the clinic between 1 January 1984 and 31 December 1997, treatment with the first AED was unsuccessful in 248 patients (53%), who constituted the present study cohort. One hundred and thirteen patients had inadequate seizure control on the first drug, 98 withdrew treatment due to adverse events (69, intolerable side effects; 29, idiosyncratic reactions), and 37 due to other reasons 2 . Fifty-two percent were male. The median follow-up period was 5 years (range 2-16 years). The median age at referral was 31 years (range 9-89 years), and the median age at onset of epilepsy was 28 years (range 1-87 years).
The percentage of successful treatment declined in each successive drug regimen (monotherapy or combination), while that of patients with inadequate seizure control rose progressively (Fig. 1) . Among the 248 patients whose epilepsy was not controlled on the first AED, 166 received a substituted drug, 61 (37%) of whom became seizure-free on this second choice. Among the 113 patients with inadequate seizure control on the first AED, 58 opted to continue on the same drug, 24 received add-on treatment, and 31 were treated with a substituted drug, only five (16%) of whom became seizure-free ( Fig. 2 , P < 0.01). Eighteen patients were not able to tolerate trials of two different AEDs, five patients three AEDs, and one was not able to tolerate even the fourth choice.
When a tolerable AED was eventually identified, it was still ineffective in 56 patients, 18 of whom then received add-on treatment and four substitution, while 34 opted to continue on the same drug. Thus, among all patients with inadequate seizure control on the first tolerated AED, 42 (24 after the first drug and 18 after subsequent drugs lacked efficacy) received addon therapy and 35 (31 after the first drug and four after subsequent drugs) received substitution. There was no significant difference in seizure-free rates (addon: 11 out of 42, 26%; substitution: 6 out of 35, 17%) or incidence of adverse events necessitating withdrawal (add-on: 5 out of 42, 12%; substitution: 9 out of 35, 26%) between the two treatments (P = 0.25) (Fig. 3) . Eleven patients received add-on therapy at a later stage after the substituted drug failed to control the seizures. None of them became seizure-free, compared to a seizure-free rate of 26% among those who received add-on as soon as the first tolerated AED failed (n = 42; P = 0.05).
A variety of AED combinations were employed (Table 1 ). Based on the drugs' perceived primary mechanisms of action, more patients became seizurefree (Fig. 4) when the combination involved a sodium channel blocker and an AED with multiple mechanisms of action (36%) compared to other combinations (7%, P < 0.05). None of the patients who received a combination of a sodium channel blocker and a 'pure' GABA-ergic agent (vigabatrin or tiagabine) became seizure-free.
DISCUSSION
The argument against add-on therapy traditionally has been its propensity to cause greater toxicity without substantial improvement in outcome 11 . However, adverse events due to pharmacokinetic and pharmacodynamic interactions between AEDs can be equally problematic during the substitution phase 20, 26 . Only 12% of our patients given combination therapy had to withdraw treatment due to side effects, which was a lower proportion, although not statistically significantly so, than those who changed to a second drug (26%). Ninety percent of the combinations employed the newer drugs, some of which are better tolerated than their older counterparts 27, 28 .
Although no significant difference in efficacy was observed between alternative monotherapy and duotherapy in our cohort, synergistic (supra-additive) effects have been demonstrated for specific combinations in comparative studies, notably sodium valproate and lamotrigine 20, 29 . This discrepancy is likely to be due to the inclusion of a relatively small number of patients taking a large number of different combinations in the present study. Indeed, when the var- 
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CBZ = carbamazepine; GBP = gabapentin; LTG = lamotrigine; OXC = oxcarbazepine; PHT = phenytoin; REM = remacemide; TGB = tiagabine; TPM = topiramate; VGB = vigabatrin; VPA = sodium valproate; GABA = γ -aminobutyric acid.
ious combinations were grouped together according to the AEDs' primary mode of action, significantly more patients given a sodium channel blocker and a drug with multiple mechanisms became seizure-free than those treated with other combinations. Combination therapy was more effective when prescribed immediately after the first drug failed due to lack of efficacy than when it was delayed until treatment with a substitution also proved unsuccessful. This difference in efficacy might reflect the severity of the underlying disease, i.e. patients unresponsive to two successive AEDs might have more 'drug resistant' epilepsy than those uncontrolled on just one drug. Whether pharmacoresistance is present de novo or evolves over time is debatable 2 . The concept of seizures begetting seizures was first hypothesized by Gowers 30 in the last century and is supported by the experimental model of kindling, whereby electrical stimulation at what is initially a subconvulsive level in an animal subsequently becomes sufficient to induce seizures after repeated application 31 .
Although clinical data in favour of the kindling hypothesis in human epilepsy is lacking 32 , there is good evidence to suggest that recurrent seizures, particularly those involving the limbic structures, can cause enduring disturbances in neuronal function [33] [34] [35] . In addition, long-term outcome studies of patients who underwent temporal lobectomy for refractory temporal lobe epilepsy suggest that secondary epileptogenesis at sites distant to the lesion may develop with uncontrolled seizures 36 . The self-perpetuating nature of seizures in some patients may account for the progressive decline in the likelihood of seizure freedom achieved with successive treatment regimens.
Findings from this observational study have relevance to the formulation of a more strategic approach in managing patients with newly diagnosed epilepsy. When the first AED failed due to lack of efficacy, the successful rate of an alternative monotherapy was only 16%, compared to 47% in drug-naïve patients. The chance of seizure freedom with pharmacological treatment after failure of two consecutive AEDs due to in-adequate efficacy (as opposed to poor tolerability) is slim. These patients should be assessed for epilepsy surgery, which can render up to 90% of appropriately selected patients seizure-free 37 . For the majority of patients not suitable for 'curative' resective surgery, these preliminary observations suggest that rational combination therapy should be employed early since its delay, like delayed surgical intervention 37 , might risk irreversible psychosocial consequences and reduce the chance of eliminating disabling seizures.
The comparisons between substitution and addon, and between the different AED combinations inevitably suffer from confounding factors, including possible bias in patient selection and non-uniformity of drug regimens. Nevertheless, observations from this study have generated verifiable hypotheses regarding the management of epilepsy after the first AED fails. Randomized trials to evaluate the effectiveness of different AED mechanistic combinations and that of early versus late combination therapy are needed. Such a study involving newly diagnosed patients is underway in Glasgow.
